RT Journal Article
SR Electronic
T1 Biochemical and Immunological Predictors of Non-healing in Individuals with Early-stage Diabetic Foot Ulcers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.09.21266108
DO 10.1101/2021.11.09.21266108
A1 Raghavan, Jayashree Vijaya
A1 Sagar, Shruthi Ksheera
A1 Dorai, Vinod Kumar
A1 Samuel, Rebecca Diya
A1 Arunachalam, Priyanka
A1 Chaluvanarayana, H C
A1 Belahalli, Pavan
A1 Kalpana, S R
A1 Jhunjhunwala, Siddharth
YR 2021
UL http://medrxiv.org/content/early/2021/11/09/2021.11.09.21266108.abstract
AB Objective The goal of this study was to identify biochemical and immunological parameters from the blood as predictors of non-healing in early-stage diabetic foot ulcers.Research Design and Methods We performed a cross-sectional prospective cohort study among individuals with early-stage foot ulcers visiting the Karnataka Institute of Endocrinology Research over a 2.5-year period. Histopathological, biochemical, and immunological data (a total of 31 parameters) from 52 individuals were collected and analyzed to determine if predictors of non-healing may be identified. Data analysis was performed using traditional univariate analyses as well as univariate and multivariable logistic regression.Results Individual histopathological and biochemical parameters did not show any differences between healed and non-healed individuals. However, conventional univariate analysis and univariate logistic regression analysis showed that the expression of the cell-surface proteins CD63, HLA-DR and CD11b on monocytes (CD14+) was significantly lower in non-healed individuals, but with moderate discriminative ability as assessed by area under the curve (AUC) of Receiver Operating Characteristics (ROC) curve. In comparison, a multivariable logistic regression model identified four of the 31 parameters to be salient predictors and demonstrated high discrimination ability with an AUC of ROC value of 0.87. Among the four identified parameters, LDL cholesterol (OR 18.83, CI 18.83-342) and cell-surface expression of CD63 on monocytes (OR 0.12, CI 0.12-0.45) were significant.Conclusion Through this study we conclude that LDL cholesterol and cell-surface expression of CD63 on monocytes are strong positive and negative predictors of non-healing, respectively, in individuals with early-stage DFU. Following validation in a larger cohort, these parameters may be used by the clinician for early identification of non-healers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support from the Rajiv Gandhi University of Health Sciences, Govt. of Karnataka (17C008B). This study was also funded in part by the Biodesign and Bioengineering Initiative (Phase II), Department of Biotechnology, Govt. of India. It was also funded by the Dr. Vijaya and Rajagopal Rao laboratory for Biomedical Engineering at IIScAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the institutional review board at the Karnataka Institute of Endocrinology Research (protocol number: IEC-KIER/04/28.10.2017). All procedures were conducted in accordance with the approved protocolI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/Immunoengineeringlab/DFU_IISc_KIER_JVR_Data. https://github.com/Immunoengineeringlab/DFU_IISc_KIER_JVR_Data